Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.
Authors
Lydia Gaba
Hospital Clinic de Barcelona, Barcelona, Spain
Lydia Gaba, Iván Victoria, Francisco Aya, Gustavo Ruiz, Estela Pineda, Òscar Reig, Aranzazu Fernandez-Martinez, Aleix Prat, Ana Arance
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Surrogate Markers of Clinical Response
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 66)
DOI
10.1200/JCO.2017.35.7_suppl.66
Abstract #
66
Poster Bd #
G9
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
First Author: Shelly Ann Christiansen
Poster
2015 ASCO Annual Meeting
Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.
First Author: Lydia Gaba
Poster
2022 ASCO Annual Meeting
A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
First Author: Geoffrey Thomas Gibney
Poster
2021 ASCO Annual Meeting
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
First Author: Olivier Jules van Not